Median OS was not reached with TECENTRIQ + Avastin vs 13.2 months with sorafenib (HR=0.58; 95% CI, 0.42, 0.79; P=0.0006) 1

NCCN Category 1, Preferred

Atezolizumab (TECENTRIQ) + bevacizumab (Avastin) is a preferred first-line systemic therapy option (Category 1) for patients with unresectable or metastatic hepatocellular carcinoma (Child-Pugh Class A) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 2*

View the full TECENTRIQ Prescribing Information

Find information on financial assistance programs for eligible TECENTRIQ patients

1L=first line; CI=confidence interval; HCC=hepatocellular carcinoma; HR=hazard ratio; NCCN=National Comprehensive Cancer Network; OS=overall survival.
*NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines® for detailed recommendations, including other preferred options.
Category 1: based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.